Abstract #4336
Advanced imaging in lesion and normal-appearing white matter over 2 years in MS patients treated with alemtuzumab
Irene Vavasour 1 , Alex MacKay 1,2 , David Li 1 , Cornelia Laule 1,3 , and Anthony Traboulsee 4
1
Radiology, University of British Columbia,
Vancouver, British Columbia, Canada,
2
Physics
and Astronomy, University of British Columbia,
Vancouver, British Columbia, Canada,
3
Pathology
and Laboratory Medicine, University of British Columbia,
Vancouver, British Columbia, Canada,
4
Medicine,
University of British Columbia, Vancouver, British
Columbia, Canada
Alemtuzumab is a multiple sclerosis (MS) therapy
designed to inhibit inflammation and prevent the
accumulation of disability. To test the potential
neuroprotective properties of the drug, we used advanced
MRI to monitor changes in myelin water fraction, T2 and
T1 within lesions and normal-appearing white matter over
2 years in MS patients treated with alemtuzumab. Data
suggests that, while on treatment, remyelination appears
more robust possibly due to an improved immunologic
milieu 6 months post-alemtuzumab. Supporting this is a
smaller T1 increase at new lesion appearance indicating
less edema and inflammation for lesions formed while
under the effects of alemtuzumab.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
